{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicjztoejzmltmfagxdjrpvzietsnqnr3ohvc3fdpz73rgpue7ncbq",
    "uri": "at://did:plc:2gbt2dlwaqovtnmxkat3tyke/app.bsky.feed.post/3mflmgvjgjy62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiautad7mmdn6cqlygupb7iienkyj7bard2mafzd7tkw4e3wnn6juy"
    },
    "mimeType": "image/jpeg",
    "size": 224009
  },
  "path": "/articles/d41586-026-00585-x",
  "publishedAt": "2026-02-24T07:11:46.667Z",
  "site": "https://www.nature.com",
  "tags": [
    "doi:10.1038/d41586-026-00585-x"
  ],
  "textContent": "Nature, Published online: 23 February 2026; doi:10.1038/d41586-026-00585-x\n\nRegenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.",
  "title": "First-of-a-kind stem-cell therapies set for approval in Japan",
  "updatedAt": "2026-02-23T00:00:00.000Z"
}